

Design and development of meat-based functional foods with walnut: Technological, nutritional and health impact

Francisco Jiménez-Colmenero^{a*}, Francisco J. Sánchez-Muniz^b, and Begoña Olmedilla-Alonso^c,
collaborators¹

^aDepartamento de Ciencia y Tecnología de Carne y Productos Cárnicos y del Pescado y Productos de la Pesca. Instituto del Frío-ICTAN (CSIC). C/ José Antonio Novais, 10. 28040-Madrid. Spain

^b Departamento de Nutrición y Bromatología I (Nutrición). Facultad de Farmacia. Universidad Complutense de Madrid. 28040-Madrid (Spain)

^c Departamento de Nutrición y Metabolismo. Instituto del Frío-ICTAN (CSIC). C/ José Antonio Novais, 10. 28040-Madrid. Spain

¹Josune Ayo, José Carballo, Susana Corades, Claudia Ruiz-Capillas, Asunción Serrano. Departamento de Ciencia y Tecnología de Carne y Productos cárnicos y del Pescado y Productos de la Pesca. Instituto del Frío-ICTAN (CSIC). C/ José Antonio Novais, 10. 28040-Madrid, Spain.

Sara Bastida, Juana Benedi, Amaia Canales, Josana Librelotto, Meritzel Nus. Departamento de Nutrición y Bromatología I (Nutrición), Facultad de Farmacia, Universidad Complutense de Madrid. 28040-Madrid, Spain.

Inmaculada Blanco Navarro, Silvia Blázquez-García, Fernando Granado-Lorencio, Carmen Herrero-Barbudo. Unidad de Vitaminas, Servicio de Nutrición. Hospital Universitario Puerta de Hierro, San Martín de Porres, 4. 28035-Madrid, Spain.

* Corresponding author. Phone: +34 91 5492300; fax: +34 91 5493627

E-mail address: fjimenez@if.csic.es (F. Jiménez-Colmenero)

1 **Abstract**

2 With growing understanding of the relationship between diet and health has come the
3 emergence of so-called functional foods. The idea of using food for health purposes and not merely
4 as a source of nutrients opens up a whole new field in the meat industry. In addition to traditional
5 presentations, there a number of ways in which the meat sector can modify the qualitative and
6 quantitative composition of meat and meat product components and produce designer foods with
7 specific properties. This entails addressing quality factors associated with different product
8 properties (sensory and technological properties, hygiene, convenience, stability, etc.), nutritional
9 value (balanced composition and bioactive substances) and their effects on physiological function
10 and health. This article reviews a comprehensive model for the development of meat-based
11 functional foods based on a presentation of the research achieved in terms of the design and
12 development of qualitatively and quantitatively modified meat products (through reformulation) in
13 nutrients associated with cardiovascular risk (walnut as a source of bioactive substances). It also
14 discusses their bioavailability and the effect of their consumption on intermediate cardiovascular
15 risk markers in humans.

16

17

18 **Key words:** Functional food; meat products, walnut, technological development; bioavailability;
19 cardiovascular disease risk

20

21 **Short title:** Walnut-enriched meat as a functional food

22 **1. Introduction**

23 Growing understanding of the relationship between diet and health is leading to new
24 insights into the effect of food ingredients on physiological function and health, inducing increased
25 consumer demand for healthy, nutritious foods with additional health promoting functions, such as
26 functional foods.

27 Over the last several decades, meat products have come under increasing scrutiny by
28 medical, nutritional and consumer groups because of the associations established between their
29 consumption (or that of a number of their constituents—fat, cholesterol, etc.) and the risk of some
30 of the major degenerative and chronic diseases (ischemic heart disease, cancer, hypertension and
31 obesity). Therefore, meat-based functional foods are being seen as an opportunity to improve the
32 “image” of meat and address consumer needs, and also to update the nutritional and dietary goals
33 (Jiménez-Colmenero, 2007a).

34 Most research into meat-based functional foods has been founded on animal production or
35 technological strategies to increase the presence of healthy compounds (Arihara, 2006; Jiménez-
36 Colmenero, 2007b; Jiménez-Colmenero, Carballo, & Cofrades, 2001; Muguerza, Gimeno,
37 Ansorena, & Astiasarán, 2004). This article reports a comprehensive approach to the design and
38 development of reformulated meat-based functional foods in which animal fat is reduced and
39 bioactive compounds (walnut) are added in appropriate amounts to achieve a functional effect. This
40 functional effect was assessed by means of an intervention study with volunteers presenting
41 increased risk of cardiovascular disease.

42

43 **2. Dietary intake and cardiovascular diseases (CVD)**

44 Diet and nutrition are important factors in the promotion and maintenance of health
45 throughout life. According to the World Health Organization (WHO) and the Food and Agriculture
46 Organization (FAO), several dietary patterns along with lifestyle habits constitute major modifiable

47 risk factors in relation to the development of non-communicable diseases, coronary heart disease
48 (CHD), cancer, type 2 diabetes, obesity, osteoporosis and periodontal disease (WHO, 2003). In
49 addition to providing nutrients to cover metabolic requirements, diet can modify specific
50 physiological functions and reduce the risk of certain diseases. Chronic diseases contribute to
51 approximately 60% of deaths, almost half of which are cardiovascular (WHO, 2003). Moreover,
52 deaths and disabilities due to CHD and strokes can be cut by more than 50% by a combination of
53 simple and effective low-cost national efforts and individual actions to reduce major risk factors
54 such as high blood pressure, high cholesterol, obesity and smoking (WHO, 2007).

55 According to the WHO (2009), by 2010 CVD will be the leading cause of death in
56 developing countries, as these are no longer only diseases of the developed world. The rise in CVD
57 reflects a significant change in dietary habits, physical activity levels, and tobacco consumption
58 worldwide as a result of industrialization, urbanization, economic development and food market
59 globalization. For instance, people nowadays consume a more energy-dense, nutrient-poor diet and
60 are less physically active. Imbalanced nutrition, reduced physical activity and increased tobacco
61 consumption are the key lifestyle factors. High blood pressure, high blood cholesterol, overweight
62 and obesity—and type 2 diabetes—are among the major biological risk factors in CVD. Unhealthy
63 dietary practices include high consumption of saturated fats, salt and refined carbohydrates and low
64 fruit and vegetable intake (WHO, 2003; WHO, 2009), whereas recommendations concerning the
65 reduction of CVD risk in industrialized countries commonly specify less fat (total, saturated and ω -
66 6 polyunsaturated—PUFAs—fatty acids and non-*trans*) (WCRF/AICR, 1997; WHO, 2003).

67

68 **3. Functional foods.**

69 Observations associating particular eating habits, mainly excessive intake of certain
70 nutrients, with the etiology and development of chronic diseases have led to the concept of
71 “optimal nutrition”. Optimal nutrition is based on a number of dietary recommendations to modify

72 (reduce or increase) the intake of certain foods or food components and the development of new
73 foods in which the original composition is modified, in terms of both nutrient and non-nutrient
74 contents. The ultimate aim is to optimize physiological functions and so maximize their
75 contribution to well-being and health and minimize the risk of diseases. It is in this context that
76 functional foods come to the fore. A food may be regarded as functional if it is satisfactorily
77 demonstrated that it beneficially affects one or more target functions in the body, over and above
78 adequate nutritional effects, in a way that is relevant to either an improved state of health and well-
79 being and/or a reduction of the risk of disease. A functional food can be a natural food, or a food to
80 or from which a component has been added or removed by technological or biotechnological means
81 (Diplock, et al., 1999). The incorporation of these products into the diet is highly desirable and
82 could have considerable public health implications, not only because it can reach broad population
83 groups but also because these diseases start at early ages and because they entail a high cost to
84 society and governments in financial terms and in terms of disability-adjusted life years.

85 The criteria required to assess the scientific basis of claims regarding food properties were
86 laid down in the course of the projects FUFOSE (Diplock et al., 1999) and PASSCLAIM (Aggett et
87 al., 2005; Asp et al., 2004). Finally, a consensus was arrived at on the scientific criteria that need to
88 be followed for purposes of assessment or design of foods for which healthy properties are claimed
89 (Aggett et al., 2005). Changes in composition are not enough for a food to be considered
90 functional; it must also be satisfactorily shown that consumption has a beneficial effect on certain
91 population groups. Trials are therefore necessary to demonstrate such an effect, preferably in
92 humans and using suitable intermediate biomarkers for early detection and prognosis of the disease
93 (Aggett et al., 2005).

94 Where it is not possible to directly measure the effect of a food in terms of health, quality of
95 life or reduced risk of disease—as in most cases concerning chronic diseases—functionality is
96 assessed by means of biomarkers. In the field of nutrition, biomarkers should be associated with a

97 future health objective, but at a stage where dietary intervention can effectively assist early
98 diagnosis or improved prognosis of the disease in question. Such markers of intermediate
99 objectives within the process of the disease must be carefully selected to allow for short-term
100 measurements that can be used later on to make inferences regarding the effects on final objectives
101 which would only normally be possible in a long-term study.

102

103 **4. Walnut and cardiovascular disease: Bioactive components**

104 Epidemiological studies show that regular consumption of nuts in general, and walnut in
105 particular (Banel & Hu, 2009; Feldman, 2002; Fitó et al., 2007; Fraser, Sabaté, Beeson, & Strahan,
106 1992; Iwamoto et al., 2000; Nus, Ruperto, & Sánchez-Muniz, 2004; Sabaté, 1993; Sabate et al.,
107 1993; Salas-Salvadó, García-Arellano et al., 2008; Salas-Salvadó, Fernández-Ballart, 2008;
108 Tyrovolas & Panagiotakos, 2009) correlates inversely with myocardial infarction and CHD
109 regardless of other factors associated with risk such as age, sex, smoking, hypertension, weight and
110 exercise. Although the exact mechanism is not understood, the positive effects of walnut intake
111 have been attributed, at least in part, to its particular lipid composition, which is characterized by a
112 high fat content (62-68 % dry matter) and abundant monounsaturated fatty acids (MUFAs, oleic
113 acid 18 % of total fatty acids) and PUFAs (linoleic and α -linolenic making up 58 and 12 %,
114 respectively of total fatty acids). In addition to these, there are other components of interest: fibre
115 (5-10 % dry matter), protein (14 % dry matter) rich in arginine, vitamins, minerals, phytosterols,
116 polyphenols, etc. (Nus et al., 2004; Ravai, 1995; Sabaté, 1993; USDA, 2005).

117 Walnuts have been selected as a potential functional component in meat products because
118 their nutritional composition has more relevance to CVD than other nuts and plant foods (e.g. ω -6
119 and ω -3 PUFAs, γ -tocopherol, arginine-rich protein) and because they are generally acceptable to
120 consumers. In addition, this approach supplies several other constituents of walnuts (e.g. plant
121 sterols, polyphenols and fibre) without substantially reducing other nutritionally important

122 components of meat such as iron and zinc (Olmedilla-Alonso, Granado-Lorencio, Herrero-Barbudo,
123 & Blanco-Navarro, 2006). The amount of walnuts to be incorporated into the final product is
124 partially based on nut and meat consumption data in Spain (INE, 1994; MAPA, 2003), data from
125 epidemiological and clinical studies with nuts, and suggestions about nut intake (FDA, 2003).

126 In response to the evidence for the beneficial health effect of walnut consumption, stress has
127 recently been placed on the importance of including them as a regular part of the diet. In this
128 context the Food and Drug Administration (FDA) has approved the possibility of a qualified health
129 claim in relation to heart disease. In particular it is permitted to state that “supportive but not
130 conclusive research shows that eating 1.5 ounces (42.5 g) of walnuts, as part of a low saturated fat
131 and low cholesterol diet and not resulting in increased caloric intake, may reduce the risk of
132 coronary heart disease” (FDA, 2003; FDA, 2004). That claim statement on walnuts and heart
133 disease has been reviewed without changes for whole or chopped walnuts (FDA, 2009). For its
134 part, the WHO (WHO, 2003) recommends consuming at least 400 g of fruit and vegetables daily, at
135 least 30 g of which should be nuts, pulses or seeds. In its global strategy programmes for CVD
136 prevention, the WHO (2009) recommends, among other dietary strategies, consuming a diet rich in
137 fruit, vegetables, nuts and whole grains.

138 Despite such notable advantages, walnut consumption generally falls short of recommended
139 levels. Not many people can be persuaded to systematically consume enough walnuts in their pure
140 state over long periods of time (every day over a long period). They are more likely to accept dishes
141 prepared with it. One way to promote walnut intake would be to use it as an ingredient in
142 frequently-consumed foods, for instance meat derivatives, to which bioactive compounds can be
143 added to render them more heart-healthy (Jiménez Colmenero et al., 2001; Sánchez-Muniz, 2004).

144

145 **5. Meat products as functional foods**

146 Meat and meat products are essential parts of the diet which concentrate and supply a large
147 number of nutrients (protein, fat, vitamins, minerals). Meat is a fundamental source of proteins of
148 high biological value. It is a well-balanced source of amino acids that satisfies human physiological
149 requirements. Meat is a good source of iron, zinc and phosphorus, with significant amounts of other
150 essential trace elements such as selenium, magnesium and cobalt, and an excellent source of B
151 group vitamins like B₁, B₂, niacin, pantothenic acid, vitamin B₆ and vitamin B₁₂ (Jiménez-
152 Colmenero, 2007a). Meat has traditionally been highly appreciated as a food of great nutritional
153 value, and meat consumption has always been associated with good health and prosperity.
154 However, over the last few years the situation has changed, among other reasons because of the
155 epidemiological associations discovered between meat and meat derivatives or some of their
156 constituents, and the risk of some of the major diseases in our society (CHD, cancer, high blood
157 pressure and obesity). Like other food-related sectors, the meat industry is in a permanent state of
158 change in response to continuous technological innovations and changes in consumer demands,
159 among which those relating to improvement of certain health-related aspects through the diet are
160 becoming increasingly important. This situation is prompting the emergence of new, “healthier”
161 meat products, prominent among them functional foods, which are the main driving force behind
162 the development of new food products, including meat-based products. Functional meat derivatives
163 present an excellent opportunity to diversify and take up positions in a tremendously important
164 emerging market (Jiménez-Colmenero, Reig, & Toldrá, 2006).

165 There are various strategies for introducing qualitative and/or quantitative modifications in
166 meat and meat derivatives in order to achieve a “functional” product, and of these, strategies
167 associated with meat processing are especially promising. The principal advantage of meat
168 derivatives in terms of modifying composition is the opportunity that they offer to change the
169 ingredients (meat and non-meat) used to produce them and hence work with various endogenous
170 and exogenous bioactive compounds. The basic idea is to be able to limit the concentration of

171 compounds with adverse physiological effects and enhance the concentration of other, beneficial
172 ones (Jiménez Colmenero et al., 2001; Jiménez-Colmenero, 2007a; Sánchez-Muniz, 2004). Most
173 physiologically active substances come from plants, and when combined with other foods such as
174 meat derivatives they can help endow a food with functional effects. The idea of using plant
175 products in the meat industry is not a new one; various types of ingredients have been used for their
176 technological, sensory, economic and nutritional effects. Because of their importance, lipids are
177 among the bioactive components that have received most attention, particularly (in quantitative and
178 qualitative terms) with respect to the development of potential meat-based functional foods
179 (Jiménez-Colmenero, 2007b). In that respect, the special characteristics of walnuts offer promising
180 perspectives for the development of functional meat products. As one of the most important
181 commonly-consumed foods, meat offers excellent ways to promote intake of functional ingredients
182 without any radical changes in eating habits.

183

184 **6. Design of meat-based functional foods with walnuts**

185 Within this context and considering the present state of and trends in meat consumption, our
186 team has embarked on the design and development of walnut-enriched functional meat-based
187 products with potential for CHD risk reduction. Within a multidisciplinary project, we address the
188 development of a functional meat product of this type using reformulation technology. Specifically,
189 our aim is to design and develop meat products qualitatively and quantitatively modified in such a
190 way as to achieve a nutrient composition profile associated with a reduced risk of CHD (Olmedilla-
191 Alonso et al., 2006).

192 The proposed design incorporates some of the strategies that are known to be effective in
193 preventing CHD (WHO, 2009), such as: limiting energy intake from total fats and shifting fat
194 consumption away from saturated fats to unsaturated fats and towards the elimination of trans-fatty
195 acids; increasing consumption of ω -3 PUFAs from fish oil or plant sources; consuming a diet rich

196 in fruits, vegetables, nuts and whole grains, and low in refined grains; avoiding excess consumption
197 of food with high content of salt and refined carbohydrates. The dietary intake of fats, and
198 especially their quality, strongly influences the risk of CVD like coronary heart disease and stroke,
199 through effects on blood lipids, thrombosis, blood pressure, arterial function, arrhythmogenesis and
200 inflammation. Excess salt has a significant impact on blood pressure levels (WHO, 2009).

201 For this purpose, several aspects had to be addressed: how much meat could be supplied to
202 be acceptable and sustainable within a balanced diet while being compatible with nutritional
203 recommendations based on the available scientific evidence, which nut(s) and what amounts should
204 and could be incorporated into the final meat product (technological challenge); and, finally, how to
205 assess the efficacy of the product for the purpose for which it had been developed (human
206 intervention trial and use of biomarkers). Walnuts were selected as a good source of nutrients
207 relevant to CVD (e.g. ω -6 and ω -3 PUFAs, γ -tocopherol, arginine-rich protein) compared to other
208 nuts and plant foods. The amount of walnuts and meat to be consumed was based on nut and meat
209 consumption data in Spain (INE, 1994; MAPA, 2003) and recommendations about nut intake (e.g.
210 FDA, 2003; Olmedilla-Alonso et al., 2006). It was thought necessary to formulate at least two types
211 of walnut-enriched meat products (for reasons of diversification), which could reasonably be
212 consumed by a large percentage of the population five times a week as part of a normal diet and
213 sustained over the long term. The study was designed to last five weeks, time enough to be sure of
214 a change in lipid profile following the dietary intervention.

215 The meat-based functional products had to contain a high concentration of walnut, and
216 therefore they were designed so that 150 g of any of them would supply ca. 70 % of the daily
217 walnut intake recommended to help reduce the risk of cardiovascular diseases (FDA, 2003). That is
218 equivalent to consuming 19.4 g walnut/day. This proposal required a reformulation of meat
219 derivatives involving compositional changes that affect protein quality, lipid content and profile,
220 and the presence of antioxidants.

221 The approach to the technological and nutritional challenges and physiological testing used
222 in the study reported below may be fully applicable to the development of other functional food
223 products.

224

225 **7. Technological development of meat products with added walnut**

226 One fundamental aspect of this research is the technological development of meat products
227 formulated with walnut, which must achieve comparable quality levels (sensory, nutritional,
228 technological, health, convenience, etc.) to those of any other meat product of similar
229 characteristics. This also includes other aspects (social, legal, etc.) unrelated to the intrinsic quality
230 of the product which affect their valuation and degree of acceptance. In accordance with the design,
231 the manufacturing process was aimed at both limiting concentrations of certain unwanted
232 compounds (animal fat, sodium) and promoting the presence of bioactive compounds (present in
233 the added walnut) with potentially beneficial effects on the onset and development of
234 cardiovascular disorders.

235 Based on strategies of this kind, two types of product were developed with clearly different
236 characteristics: *restructured steaks* and *frankfurters* (gel/emulsion systems). These kinds of
237 products were chosen for their special interest. Restructured steaks belong to a range of foods
238 which offer major advantages in industrial terms and can readily satisfy all consumer requirements
239 (appearance, composition, texture, constant quality, convenience, etc.). Then frankfurters belong to
240 a group of derivatives of major economic importance which are widely accepted throughout the
241 world.

242 The technological approach, manufacturing and preparation procedures, physicochemical
243 and sensory characteristics, storage stability and cooking behaviour of the new derivatives were
244 evaluated. Following is a brief account of the studies carried out, highlighting the impact of various
245 variables on the physicochemical and sensory characteristics of the products as influenced by

246 various factors assayed in the technological manufacturing processes.

247

248 *7.1 Restructured steaks*

249 One essential aspect of this research was analysis of the influence of the percentage of
250 added walnut (0, 5, 10 and 20 %) on the characteristics of the protein matrix (physicochemical
251 properties, microstructure) and sensory attributes of restructured steaks (Cofrades et al., 2004a;
252 Jiménez-Colmenero et al. 2003; Serrano, Cofrades, & Jiménez-Colmenero, 2004). Although adding
253 walnut produces certain changes in the matrix, the resulting products presented acceptable
254 physicochemical and sensory characteristics. One of the conditioning factors analysed was the
255 effect of the degree of structural disintegration of the meat on the influence of added walnut on
256 product characteristics (Cofrades et al., 2004a). Restructured steaks were formulated with walnut
257 using thermal gelation and cold gelation with microbial transglutaminase. Thermal gelation was
258 used to evaluate the consequences of changing the formulation for purposes of marketing as a
259 frozen product (Jiménez Colmenero et al., 2003) or a pre-cooked product (Cofrades et al., 2004b).
260 Cold gelation procedures were used to make steaks containing different concentrations of walnut
261 (0, 10 and 20%) for chilled storage (Serrano et al., 2004).

262 In order to improve the outward appearance of the restructured steaks, a number of protein
263 coatings were assayed. The idea was, once the steak was made, to coat it with a protein film that
264 would lend it the appearance of a conventional steak. The development of the product, the
265 application and technology of the coating preparation and various other aspects reported in this
266 article are all protected by patent (Spanish Patent Application N° 200300367; Spanish Patent
267 Application N° 200400548).

268 The reformulation of meat products to enhance health-beneficial components, as in the case
269 of added walnut, produces qualitative and quantitative changes in the composition (protein, lipids
270 and others components) of meat products (Serrano et al. 2005). Some of these changes can

271 influence the product's response to different technological treatments, and hence its chilling and
272 frozen stability. Studies on chilling storage with special emphasis on microbiological aspects and
273 the formation of biogenic amines (Ruiz-Capillas, Cofrades, Serrano, & Jiménez-Colmenero, 2004),
274 and on frozen storage with special emphasis on lipid oxidation (Serrano, Cofrades, & Jiménez-
275 Colmenero, 2006) have shown that the presence of walnut is not a limiting factor for product
276 stability.

277 Restructured beef steak, like other foods, will normally be cooked prior to consumption.
278 Heat treatment has a significant impact on the composition and physicochemical characteristics of
279 final food products; indeed, it is well known that meat product composition (fat content, added non-
280 meat ingredients) and cooking techniques are among the factors most affecting the final quality
281 attributes of the product. The influence of various cooking methods—grilling, conventional oven,
282 microwave oven and pan-frying—on the composition and physicochemical characteristics of
283 restructured beef steaks has been investigated by Serrano, Librelotto, Cofrades, Sánchez-Muniz and
284 Jiménez-Colmenero (2007). No limitations were observed due to different cooking procedures
285 (roasting, grilling and pan-frying) on the physicochemical characteristics of restructured steaks
286 containing walnut. Despite their high polyunsaturated fat content, lipid oxidation of restructured
287 beef steak containing walnut was low after all cooking procedures. The high lipid retention of
288 walnut restructured steaks during cooking assures a healthy food profile at the moment of ingestion
289 (Serrano et al., 2007). More specific studies have been conducted on the effect of pan-frying in
290 extra virgin olive oil on the fatty acid profile and fatty acid retention and thermal oxidation of
291 restructured functional steaks (Librelotto et al., 2008) and on long frozen storage stability of the
292 same product (Librelotto, Bastida, Zulin-Botega, Jiménez-Colmenero, & Sánchez-Muniz, 2009).
293 This culinary technique produced fried steaks with low lipid alteration (oxidative and hydrolytic).
294 Moreover, the atherogenic and thrombogenic indices of these pan-fried restructured steaks were

295 much lower than those of reduced- or medium-fat counterparts, so that the meat was highly
296 acceptable from a nutritional and a CVD point of view (Librelotto et al., 2009).

297

298 *7.2 Frankfurters*

299 Alongside the research on restructured steaks, several studies have been conducted to
300 address the technological challenge also posed by reformulation (design and development) of meat
301 products based on gel/emulsion systems. These have assessed how the presence of different
302 amounts of walnut (7, 14 and 21%) influences the characteristics (physicochemical, morphological
303 and sensory) of meat emulsion products, in this case frankfurters. Morphology, textural parameters
304 (hardness, cohesiveness and chewiness), fat- and water-binding properties and colour were all
305 influenced by the level of walnut addition. Generally speaking, products with added walnut have
306 presented sensory attributes acceptable to consumers (Ayo, Solas, Carballo, & Jiménez-Colmenero,
307 2004; Carballo, Ayo, & Jiménez-Colmenero, 2003). In order to limit sodium levels, various studies
308 have been conducted to assess the effect of several salt levels on products containing walnut (Ayo,
309 Jiménez-Colmenero, Carballo, & Ruiz-Capillas, 2004) and analyse the use of transglutaminase in
310 meat batters with different percentages of walnut and without salt (Cofrades et al., 2004b). On the
311 basis of these results a study was conducted to compare products (with added walnut and no salt)
312 formulated with combinations of transglutaminase and a number of non-meat ingredients
313 (caseinate, KCl and wheat fibre) as salt replacers, with a product containing normal salt levels. The
314 results suggest that some of the combinations assayed could be used to compensate for the absence
315 of salt in the preparation of sausages containing walnut (Jiménez-Colmenero, Ayo, & Carballo,
316 2005).

317 We would note in a general way that the quality attributes of the meat products developed—
318 restructured steaks and frankfurters—containing 20 % of walnut were acceptable in terms of
319 physicochemical and sensory properties and stability.

320

321 **8. Nutritional profile of meat products with added walnut.**

322 The potential functional effect of walnut in meat-based functional foods derives from
323 various constituents with health implications. Studies have been conducted both on restructured
324 steaks (Serrano et al., 2005) and on frankfurters (Ayo et al., 2007) to determine how the walnut
325 affects the nutritional profile. Compared with control products (0 % added walnut), the product
326 with added walnut (20-25 %) presented a lower lysine/arginine ratio, larger quantities of MUFAs
327 and ω -3 PUFAs (mainly α -linolenic acid), a lower ω -6/ ω -3 PUFA ratio and a higher PUFA/SFA
328 ratio. In restructured beef steak (13 % fat) formulated with 20 % added walnut, around 90 % of the
329 fat content came from walnut; MUFAs and PUFAs together accounted for almost 90 % of total
330 fatty acids, with ω -6/ ω -3 PUFA < 4 and PUFA/SFA > 6.5 (Table 1). The addition of 20 % walnut
331 also furnished around 1 % of dietary fibre. Energy content was 99 kcal/100g (414.2 kJ/100g) in the
332 control sample (1.6 % fat content, no walnut added) and 213 kcal/100 g (891.2 kJ/100g) in the
333 walnut (20 %) enriched product (14.5 % fat content), approximately 62 % of energy from fat.
334 Replacement of raw meat material by walnut reduced the cholesterol content and increased (more
335 than 400 fold) the amount of γ -tocopherol. Meat products with added walnut could be good sources
336 of manganese, iron, copper, potassium and magnesium, supplying high percentages (15-40 %) of
337 the daily recommended intakes for these minerals.

338 The γ -tocopherol content of restructured meat products is of particular interest as the
339 exposure biomarker chosen in the intervention study to assess the functionality of the products
340 designed—walnut-enriched steaks containing over 4000 μ g γ -tocopherol/100g (Table 1), walnut-
341 enriched sausages containing 4980 μ g γ -tocopherol/100g and walnut-free steaks containing ca. 19
342 μ g γ -tocopherol/100g (Olmedilla-Alonso, Granado-Lorencio, Herrero-Barbudo, Blanco-Navarro, &
343 Sánchez-Muniz, 2005; Olmedilla-Alonso et al., 2006).

344

345 **9. Assessing the effect of meat-based functional products on cardiovascular disease risk.**

346 A 5-week randomized, placebo-controlled crossover study was conducted on subjects at risk
347 of CVD (n=25) to assess the functional effect of consumption of restructured steaks and
348 frankfurters containing 20 % walnut. For five weeks, instead of meat and meat derivatives the
349 volunteers consumed five meat products (4 steaks and 1 sausage, with or without added walnut) per
350 week (150 g meat product/ helping). The habitual consumption of a mixed diet (no avoidance of
351 any groups) was required. In terms of equivalent walnut consumption, that would be 30 g
352 walnut/steak and 16 g walnut/helping of sausages. This means consuming 136 g of walnuts per
353 week, giving an average intake of 19.4 g walnuts/day, which is ca. 70 % of the amount of walnuts
354 suggested by the (FDA, 2004; FDA, 2009).

355 Men and women were selected who had at least four CVD risk factors as identified by the
356 WHO/FAO in their report on prevention of chronic diseases through diet (WHO, 2003). Inclusion
357 criteria were: age (men: 45-65, women: 50-70 years and postmenopausal), overweight (BMI > 25
358 and < 34.90 kg/m²), serum cholesterol > 220 and < 290 mg/dl, and at least one of the following
359 features: smoking habit and/or blood pressure \geq 140/90 mm Hg.

360 The bioavailability of walnut components contained in the new products was assessed
361 beforehand by means of a postprandial (single-dose) study in three volunteers using γ -tocopherol as
362 an exposure marker. The reason for choosing this compound was that consumption of the meat
363 product with added walnuts supplies significantly more γ -tocopherol (ca. 29 mg γ -tocopherol per
364 week) than is normally supplied by our diet (Olmedilla-Alonso et al., 2005). Consumption of a
365 restructured meat product caused an increase in γ -tocopherol in the triglyceride-rich lipoprotein
366 fraction during the postprandial period only when walnuts were added. The increase peaked 6 hours
367 after intake (time evaluated: 6 h). This provides *in vivo* evidence of the efficacy of walnut-enriched
368 restructured meat products as a vehicle for bioactive substances, e.g. γ -tocopherol (Olmedilla-
369 Alonso et al., 2008).

370 The functional effects were assessed using clinically relevant and related biomarkers of CHD:
371 1) biomarkers of function: a) used in clinical practice: cholesterol (total, LDL-cholesterol and
372 HDL-cholesterol), triacylglycerols, blood pressure and homocysteine; b) biomarkers sensitive to
373 dietary changes and associated with CVD risk: folic acid, vitamins B₆ and B₁₂, α -tocopherol, serum
374 γ -tocopherol, and platelet function test; c) other biomarkers: eicosanoids (e.g. Thromboxan A₂,
375 prostacyclin I₂, leukotrien B₄), Lp(a), apolipoprotein (Apo) A1, Apo B, platelet aggregation,
376 inflammation markers (PCR and adhesion of monocytes VCAM and ICAM), lipid peroxidation
377 (oxidized LDL, LPO), antioxidant status based on the activity of catalase (CAT), superoxide
378 dismutase (SOD), total glutathione, reduced glutathione (GSH) and oxidized glutathione (GSSG) in
379 red cells and the activities of paraoxonase (PON-1), arylesterase in plasma; 2) biomarkers of
380 CHD/CVD risk: total cholesterol, LDL-cholesterol and systolic and diastolic blood pressure.

381 Although several markers have been proposed to study the relationship between diet and
382 CVD, (Aggett et al., 2005; Contor & Asp, 2004; Mensink et al., 2003), only LDL-cholesterol and
383 blood pressure are well-established markers generally accepted as related to changes in risk of
384 CVD, although they are not direct measures of CHD incidence. Diet-related changes in cholesterol
385 and blood pressure could allow claims for enhanced function and would also support disease risk
386 reduction claims.

387 The effect of the consumption of restructured meat products with and without added
388 walnuts was evaluated by means of the above mentioned biomarkers of function and CHD-related
389 risk. Table 2 shows the ones most commonly used in clinical practice (along with γ -tocopherol as
390 exposure biomarker). On comparing concentrations after the diet containing walnut-enriched meat
391 products with the baseline (habitual mixed diet), there was a decrease in total cholesterol (10.7
392 mg/dl), LDL-cholesterol (7.6 mg/dl) and body weight (0.5 kg) and a slight decrease in systolic
393 pressure, as well as an increase in γ -tocopherol (8.9 μ g/dl). Other biomarkers such as

394 homocysteine, folate and vitamins B₆ and B₁₂ remained within normal ranges, as did platelet
395 function (measured as obturation time) (Olmedilla-Alonso et al., 2008)

396 HDL-cholesterol, fasting triacylglycerols and plasma homocysteine are established
397 examples of markers sensitive to dietary factors and have been validated methodologically, but it is
398 not yet clear to what extent changes in these markers reflect improved state of health and well being
399 and performance and reduction of disease risk. For haemostatic function and oxidative damage,
400 there is a need to develop and validate markers of improved state of health and disease risk
401 reduction that are sensitive to dietary changes (Aggett et al., 2005).

402 In this study we expected no changes in body weight, as the dietary intervention only
403 involved the substitution of meat sources in the diet. However, three volunteers out of 25 registered
404 small but significant reductions in body weight with the consumption of walnut-enriched meat with
405 respect to that of the low-fat restructured meat. Weight loss has also been reported in other studies
406 likewise involving a control group and adjusting for energy (Iwamoto et al., 2002), and in a recent
407 prospective study in which increased nut consumption was not associated with greater body weight
408 gain during eight years of follow-up in healthy middle-aged women; instead, it was associated with
409 a slightly lower risk of weight gain and obesity (Bes-Rastrollo et al., 2009).

410 Studies have been conducted comparing the effect of consumption of walnut-enriched
411 restructured steak and frankfurter with that of consumption of low-fat meat products on different
412 markers of antioxidant status (Canales et al., 2007) and of platelet aggregation and thrombogenesis
413 (Canales et al., 2009). This intervention study was the first to evaluate the effect on those
414 parameters of the intake of meat products with added walnut in subjects at high risk of developing
415 CHD. Erythrocyte catalase (CAT), superoxide dismutase (SOD), total glutathione, reduced
416 glutathione (GSH), oxidized glutathione (GSSG), lipid peroxidation (LPO), and serum uric acid
417 and paraoxonase-1 (PON-1) were all tested in increased-CHD-risk individuals consuming meat
418 products with added walnut with respect to the same individuals consuming control products.

419 Present data clearly show that the intake, 5 times per week, of meat products with added
420 walnut for 5 weeks increased concentrations/activities of several antioxidant defence biomarkers,
421 such as CAT, SOD, PON1, total glutathione, GSH and GSSG in those volunteers (Canales et al.,
422 2007) (Figures 1 and 2). Natural defence against ROS involves a number of enzymatic and non
423 enzymatic antioxidant mechanisms (Sies, 1991). The particular composition of walnuts (and thus,
424 of walnut enriched meat), which are rich in antioxidant compounds such as vitamin E, α -
425 tocopherol, γ -tocopherol, δ -tocopherol, folic acid and vitamin C (Nus et al., 2004; Olmedilla-
426 Alonso et al., 2006; Ravai, 1995; USDA, 2005), seems to be responsible for improving the
427 antioxidant status of study participants.

428 The intake of meat products with added walnut increased PON-1 activity irrespective of
429 HDL-C levels, which were not affected by the treatment. This corroborates results of other studies
430 (Almario, Vonghavaravat, Wong, & Kasim-Karakas, 2001). The increase in PON-1 concentrations
431 is presumably a consequence of the intake of a relatively large amount of PUFAs, counterbalanced
432 by the consumption of nut antioxidants. Many other authors have investigated the influence of diet
433 on PON-1 activity, but available results are controversial. The consumption of meat products with
434 added walnut induced a reduction of ~34% LPO concentration in erythrocytes as compared to
435 approximately ~8% in the control products. These results suggest that lipid peroxidation is not
436 increased by meat products with added walnut consumption despite their higher PUFA content.
437 Haque et al. (2003) found that an aqueous extract of walnut reduced the LPO content in liver and
438 kidney of mice induced by chemotherapy toxicity.

439 Platelet aggregation, plasma thromboxane (TX) A_2 (measured as TXB_2), prostacyclin I_2
440 (measured as 6-keto-PGF $_{1\alpha}$) production and the $TXB_2/6$ -keto-PF $_{1\alpha}$ ratio were determined at
441 baseline and at wk 3 and 5 for the two dietary periods (Canales et al., 2009). As indicated, the diet
442 including meat products with added walnut contained lower SFA and higher PUFA concentrations
443 and presented a more favourable ω -6/ ω -3 ratio than the diet including control meat products, which

444 accounts for the larger variations in maximum aggregation values observed at week 5 [9.62 ± 0.67
445 to 8.28 ± 0.56 cm/5 min ($p < 0.05$) in walnut enriched meat *versus* 10.35 ± 0.52 to 10.30 ± 0.66 cm/5
446 min ($p > 0.05$) in control meat] (Canales et al., 2009). The lower linoleic to linolenic acid ratio of the
447 diet including products with added walnut, together with other walnut compounds, should affect
448 platelet reaction capacity (Chan et al., 1993). At week 5, significant differences ($P < 0.05$) between
449 treatments were found for maximum aggregation rate, TXB₂ values and the TXB₂/6-keto-PF₁α
450 ratio. The effects on TXB₂ and the TXB₂/6-keto-PF₁α ratio were time-course dependent (Canales et
451 al., 2009).

452 Platelet aggregation is modulated by the production of TXA₂ and PGI₂. An optimal balance
453 of TXA₂/PGI₂ may be important in the prevention of thrombotic conditions. The diet including
454 walnut-enriched meat products contains a lower concentration of SFA and presents
455 linoleic/linolenic and ω-6/ω-3 PUFA ratios that are 2.5 times lower than those of the diet including
456 non-walnut-enriched meat products, which would account, at least partially, for the results.
457 Proanthocyanidins, naturally occurring plant metabolites commonly found in fruits, vegetables,
458 nuts, seeds, flowers and bark (Bagchi et al., 1997; Fine, 2000), form part of a specific group of
459 polyphenolic compounds called flavonoids (Bravo, 1998). These compounds are reported to have
460 anti-inflammatory and vasodilatory properties (Bagchi et al., 1997; Bagchi et al., 1998), to inhibit
461 lipid peroxidation, platelet aggregation and capillary permeability and to affect, among others, the
462 phospholipase A₂, cyclooxygenase and lipoxygenase enzyme systems (Bagchi et al., 1997; Bagchi
463 et al., 1998; Murray & Pizzorno, 1999; Robert et al., 1990). Moreover, it has been suggested that
464 tocopherol may reduce thrombogenesis (Robert et al., 1990; Szczeklik, Grylewski, Domagala,
465 Dworski, Basista, 1985).

466 However, the inter-individual variability of these findings was also striking (Canales et al.,
467 2009; Nus et al., 2007), and genetic factors may influence the results. It was therefore hypothesized
468 that volunteers at increased CHD risk having different polymorphisms in CVD gene candidates

469 respond differently to the intake of restructured beef steaks and sausages containing walnuts in
470 terms of platelet aggregation, TXA₂, PGI₂ and the thrombogenic ratio (TXA₂/PGI₂), and
471 antioxidant status (e.g. erythrocyte CAT, SOD, total glutathione, GSH and GSSG). To this end the
472 population that was defined was screened for polymorphisms for APOA4 (Canales et al., 2010) and
473 PON-1 genes (unpublished data). Although modifications in dietary cholesterol and saturated fat
474 affect plasma lipids differently in carriers of each *APOA4* variant (Herron, Lofgren, Adiconis,
475 Ordovás, & Fernández, 2006; Hubacek et al., 2007), to date there have been no studies on the
476 effect of an *APOA4* polymorphism on thrombogenesis. Moreover, no data are available on the
477 effect of *APOA4* polymorphism and the varied response to walnut consumption in individuals at
478 increased CVD risk.

479 PON-1, a HDL-bound enzyme, may be involved in lipoprotein-phospholipid metabolism
480 and may also inhibit lipid peroxide generation in LDL (Canales & Sánchez-Muniz, 2003; Mackness
481 et al., 1998; Nus, Sánchez-Muniz, & Sánchez-Montero, 2006). Available data suggest that PON-1
482 is likely to be more active in the absence of antioxidants. PON-1 exists in 2 major polymorphic
483 forms which include the replacement of glutamine (Q) by arginine (R) at position 192 (Adkins,
484 Gan, Mody, & La Du, 1993) and of leucine (L) by methionine (M) at position 55 (Garin et al.,
485 1997). It has been postulated that the ability of HDL to protect LDL against peroxidation *in vitro* is
486 significantly lower in HDL particles from PON-1-R192 (Aviram et al., 2000) than in PON-1-Q192
487 carriers.

488 Although the results have not yet been fully evaluated and discussed, the data suggest that
489 the decrease of TXB₂ levels and the TXB₂/6-keto-PGF₁α ratio in APOA4-2 with respect to
490 APOA4-1 carriers after the 5-wk treatment was significantly greater in the diet including walnut-
491 enriched products than in the diet including non-walnut-enriched counterparts. Also, our results
492 revealed a different response of antioxidant status in meat products (walnut-enriched vs. non-
493 walnut-enriched) depending on PON-1 polymorphisms. Unpublished data suggest that the changes

494 in antioxidant status markers at week 5 in meat products with added walnut with respect to the
495 control were greater in PON-1(QQ)¹⁹² polymorphism carriers than in PON-1 (QR+RR)¹⁹²
496 carriers (data not shown).

497

498 **10. Concluding remarks**

499 In functional foods, if in addition to achieving quality attributes comparable to those of any
500 other product we wish to assure the presence, absence or reduction of a nutrient or other substance
501 that we know to produce a potential beneficial effect—which has to be established with generally
502 accepted scientific data—then design and development are essential steps.

503 The design and development of potentially functional meat products based on the addition
504 of walnut has been addressed as part of a project whose goals range from the design and
505 development of meat products in which nutrients associated with CVD risk are qualitatively and
506 quantitatively modified to the study of bioavailability and the effect of consumption on
507 intermediate markers of CVD risk in humans. By using technological strategies in the
508 reformulation of meat matrixes, it has been possible to achieve products with a specific
509 composition (less animal fat and sodium and fortified with various bioactive compounds) which
510 present acceptable quality attributes in terms of physicochemical and sensory properties and
511 stability.

512 Our assessment of the effect of meat-based functional products on subjects at CVD risk
513 suggests that since regular consumption of meat products containing walnuts produces (i) a
514 reduction in intermediate clinical markers of CHD (such as total and LDL cholesterol), (ii) an
515 improvement in antioxidant status and (iii) a reduction in thrombogenesis markers, they may be
516 considered products that meet the requirements of functional foods for subjects at high risk of CVD
517 like the ones included in the present study. As the walnut was used whole, the observed effects may

518 be associated with its peculiar blend of nutrient and phytochemical compounds but cannot be
519 related to any individual ingredient.

520 Genotyping studies in ample populations should be performed in order to ascertain the
521 actual target subjects for this functional meat.

522 In view of the observed benefits accruing from the consumption of walnut-enriched meat,
523 meat industries should seriously consider making and marketing meat products of this kind, and
524 consumers should not hesitate to consume them. Nonetheless, more studies are still desirable to test
525 the effect of long-term consumption of this kind of meat products.

526

527 **Acknowledgements**

528 This research was supported under projects AGL2001-2398-C03 and Consolider-Ingenio 2010.
529 CARNISENUSA CSD2007-00016. Plan Nacional de Investigación Científica, Desarrollo e
530 Innovación Tecnológica (I+D+I), Ministerio de Ciencia y Tecnología. Spain. Thanks are due to “La
531 Morella Nuts, S. A.” and Bernardo Josa Quilez for supplying the walnuts

532

533 **References**

534

535 Adkins, S., Gan, K. N., Mody, M., & La Du, B. N. (1993). Molecular basis for the polymorphic
536 forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for
537 the respective A or B allozymes. *The American Journal of Human Genetics*, 52, 598-608.

538 Aggett, P. J., Antoine, J-M., Asp, N-G., Bellisle, F., Contor, L., Cummings, J. H., Howlett, J, *et al.*
539 (2005). PASSCLAIM. Process for the assessment of scientific support for claims on foods.
540 Consensus on criteria. *European Journal of Nutrition*, (Suppl.1), 44, 1-31.

541 Almario, R.U., Vonghavaravat, V., Wong, R., & Kasim-Karakas, S. E. (2001). Effects of walnut
542 consumption on plasma fatty acids and lipoproteins in combined hyperlipidemia. *American*
543 *Journal of Clinical Nutrition*, 74, 72-79.

544 Arihara, K. (2006). Strategies for designing novel functional meat products. *Meat Science*, 74, 219-
545 229.

546 Asp, N.G., Cummings, J.H., Howlett, J., Rafter, J., Riccardi, G., & Westenhoefer, J. (Guest
547 Editors) (2004). Process for the Assessment of Scientific Support for Claims on Foods.
548 Phase Two: Mowing Forward. *European Journal of Nutrition*, 43(supl.2), 1-30.

549 Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D.,
550 & Rosenblat, M. (2000). Human serum paraoxonase (PON-1) Q and R selectively decrease
551 lipid peroxides in human coronary and carotid arteriosclerotic lesions. *Circulation*, 101,
552 2510–7.

553 Ayo, J., Carballo, J., Serrano, J., Olmedilla-Alonso, B., Ruiz-Capillas, C., & Jiménez-Colmenero,
554 F. (2007). Effect of total replacement of pork backfat with walnut on nutritional profile of
555 frankfurters. *Meat Science*, 77, 173-181.

556 Ayo, J., Jiménez Colmenero, F., Carballo, J., & Ruiz-Capillas, C. (2004). Physicochemical
557 properties of meat batters with added walnut: Effect of salt levels. Proceeding of the 50th
558 International Congress Meat Science and Technology, Helsinki Finland.

559 Ayo, J., Solas, M. T., Carballo, J., & Jiménez-Colmenero, F. (2004). Microestructura de emulsiones
560 cárnicas: efecto de la incorporación de nuez y de la aplicación de altas presiones.
561 Proceedings of the X Congreso Anual de Ciencia y Tecnología de los Alimentos.
562 Universidad Complutense Madrid. Madrid. Spain.

563 Bagchi, D., Garg, A., Krohn, R. L., Bagchi, M., Bagchi, D. J., Balmoori, J., & Stohs, S. J. (1998).
564 Protective effect of grape proanthocyanidins and selected antioxidants against TPA-induced

565 hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage
566 activation in mice. *Gen Pharmacology*, 30, 771-776.

567 Bagchi, D., Garg, A., Krohn, R. L., Bagchi, M., Tran, M. X., & Stohs, S. J. (1997). Oxygen free
568 radical scavenging abilities of vitamin C and E, and a grape seed proanthocyanidin extract in
569 vitro. *Research Communications in Molecular Pathology and Pharmacology*, 95, 79-189.

570 Banel, D. K., & Hu, F. B. (2009). Effects of walnut consumption on blood lipids and other
571 cardiovascular risk factors: a meta-analysis and systematic review. *American Journal of*
572 *Clinical Nutrition*, 90, 56-63.

573 Bes-Rastrollo, M., Wedick, N., Martínez-González, M. A., Li, T. Y., Sampson L., & Hu, F. B.
574 (2009). Prospective study of nut consumption, long-term weight change, and obesity risk in
575 women. *American Journal of Clinical Nutrition*, 89, 1913-1919.

576 Bravo, L. (1998). Polyphenols: chemistry, dietary sources, metabolism, and nutritional
577 significance. *Nutrition Review*, 56, 317-333.

578 Canales, A., Bastida, S., Librelotto, J., Nus, M., Sánchez-Muniz, F. J., & Benedí, J. (2009). Platelet
579 aggregation, eicosanoid production and thrombogenic ratio in individuals at high
580 cardiovascular risk consuming meat enriched in walnut paste. A crossover, placebo-
581 controlled study. *British Journal of Nutrition*, 102, 134-141.

582 Canales, A., Benedí, J., Nus, M., Librelotto, J., Sánchez-Montero, J.M., & Sánchez-Muniz, F. J.
583 (2007). Effect of walnut-enriched restructured meat in the antioxidant status of
584 overweight/obese senior subjects with at least one extra CHD-risk factor. *Journal of the*
585 *American College of Nutrition*, 26, 225-232.

586 Canales, A., Benedí, J., Bastida, S., Corella, D., Guillén, M., Librelotto, J., Nus, M., & Sánchez-
587 Muniz, F. J. (2010). ApoA4 polymorphism modifies the effect of consuming meta enriched
588 in walnut paste on thrombogenesis. A controlled cross-over study. *Nutrición Hospitalaria*
589 (MS# 4504).

590 Canales, A., & Sánchez-Muniz, F. J. (2003). Paraoxonase, something more than an enzyme?.

591 *Medicina Clinica (Barcelona)*, 121, 537–548.

592 Carballo, J., Ayo, J., & Jiménez Colmenero, F. (2003). Efecto de la incorporación de nuez en las

593 propiedades físico-químicas de emulsiones cárnicas. Proceedings of the II Congreso

594 Nacional de Ciencia y Tecnología de los Alimentos. Universidad Miguel Hernández

595 (UMH). Orihuela, Spain. Editado por UMH, Vol. II, 469-472.

596 Chan, J. K., McDonald, B. E., Gerrard, J. M., Bruce, V. M., Weaver, B. J., & Holub, B. J. (1993).

597 Effect of dietary alpha-linolenic acid and its ratio to linoleic acid on platelet and plasma

598 fatty acids and thrombogenesis. *Lipids*, 28, 811-817.

599 Cofrades, S., Serrano, A., Ayo, J., Carballo, J., Ruiz-Capillas, C., & Jiménez-Colmenero, F.

600 (2004b). Effect of walnut, microbial transglutaminase and storage time on the water and fat

601 binding capacity of salt-free beef batters. *Proceeding of the 50th International Congress*

602 *Meat Science and Technology*, Helsinki Finland.

603 Cofrades, S., Serrano, A., Ayo, J., Solas, M. T., Carballo, J., & Jiménez-Colmenero, F. (2004a).

604 Restructured beef with different proportions of walnut as affected by meat particle size.

605 *European Food Research Technology*, 218, 230-236.

606 Contor, L., & Asp, N. G. (2004). Process for the assessment of scientific support for claims on

607 foods. Phase two: moving forward. *European Journal of Nutrition*, 43(sup.2), II/3-II/6.

608 Diplock, A. T., Aggett, P. J., Ashwell, M., Bornet, F., Fern, E. B., & Roberfroid, M. B. (1999).

609 Scientific concepts of functional foods in Europe: Consensus Document. *British Journal of*

610 *Nutrition*, 81 (suppl.1), S1-S27.

611 FDA (2003). Food and Drug Administration. Office of Nutritional Products, Labelling and Dietary

612 Supplements. Qualified Health Claims: Walnuts and Coronary Heart Disease (Docket No

613 02P-0292).

614 <http://www.fda.gov/Food/LabelingNutrition/LabelClaims/QualifiedHealthClaims/ucm0729>
615 10.htm Accessed 06/22/2009

616 FDA (2004). Moves Forward on Qualified Health Claims.
617 <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108273.htm>.
618 Accessed 06/18/2009

619 FDA (2009). Food and Drug Administration. Office of Nutritional Products, Labeling and Dietary
620 Supplements Qualified Health Claims Subject to Enforcement Discretion. Walnuts and
621 heart disease.
622 <http://www.fda.gov/Food/LabelingNutrition/LabelClaims/QualifiedHealthClaims/ucm0739>
623 92.htm Accessed 06/18/2009

624 Feldman, E. B. (2002). The scientific evidence for a beneficial health relationship between walnuts
625 and coronary heart disease. *Journal of Nutrition*, 132, 1062S-1101S.

626 Fine, A. M. (2000). Oligomeric proanthocyanidin complexes: History, structure, and
627 phytopharmaceutical applications. *Alternative Medicinal Review*, 5:, 44-151.

628 Fitó, M., Guxens, M., Corella, D., Sáez, G., Estruch, R., de la Torre, R., Francés, F., Cabezas, C.,
629 López-Sabater, M.C, Marrugat, J., García-Arellano, A., Arós, F., Ruiz-Gutierrez, V., Ros,
630 E., Salas-Salvadó, J., Fiol, M., Solá, R., & Covas, M. I. for the PREDIMED Study
631 Investigators. (2007). Effect of a traditional Mediterranean diet on lipoprotein oxidation: a
632 randomized controlled trial. *Archives of Internal Medicine*, 167, 195-1203.

633 Fraser, G. E., Sabaté, J., Beeson, W. L., & Strahan, T. M. (1992). A possible protective effect of
634 nut consumption on risk of coronary heart disease: the Adventist Health Study. *Archives of*
635 *Internal Medicine*, 152, 1416-1424.

636 Garin, M. C., James, R. W., Dussoix, P., Blanché, H., Passa, P., Froguel, P., & Ruiz, J. (1997).
637 Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of

638 the enzyme. A possible link between the paraoxonase gene and increased risk of
639 cardiovascular disease in diabetes. *Journal of Clinical Investigation*, 99, 62-66.

640 Haque, R., Bin-Hafeez, B., Parvez, S., Pandey, S., Sayeed, I., Ali, M., & Raisuddin, S. (2003).
641 Aqueous extract of walnut (*Juglans regia* L.) protects mice against cyclophosphamide-
642 induced biochemical toxicity. *Human Experimental Toxicology*, 22, 473-480.

643 Herron, K. L., Lofgren, I. E., Adiconis, X., Ordovas, J. M., & Fernandez, M. L. (2006).
644 Associations between plasma lipid parameters and APOC3 and APOA4 genotypes in a
645 healthy population are independent of dietary cholesterol intake. *Atherosclerosis*, 184, 113-
646 120.

647 Hubacek, J. A., Bohuslavova, R., Skodova, Z., Pitha, J., Bobkova, D., & Poledne, R. (2007).
648 Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to
649 dietary change. *Clinical Chemistry and Laboratory Medicine*, 45, 316-320.

650 INE (Instituto Nacional de Estadística). (1994). Encuesta de Presupuestos Familiares, 1990-1991.
651 Vol. 2. Madrid.

652 Iwamoto, M., Imaizumi, K., Sato, M., Hirooka, Y., Sakai, K., Takeshita, A., & Kono M. (2002).
653 Serum lipid profiles in Japanese women and men during consumption of walnuts. *European*
654 *Journal of Clinical Nutrition*, 56, 629-637.

655 Iwamoto, M., Sato, M., Kono, M., Hirooka, Y., Sakai, K., Takeshita, A., & Imaiuzumi, K. (2000).
656 Walnuts lower serum cholesterol in Japanese men and women. *Journal of Nutrition*, 130,
657 171-176.

658 Jiménez-Colmenero, F. (2007a). Meat based functional foods. In: Hui Y. H., Associate editors,
659 Chandan et al.(eds), *Handbook of Food Products Manufacturing*. (pp. 989-1015). New
660 Jersey: John Wiley & Son, Inc.

661 Jiménez-Colmenero, F. (2007b). Healthier lipid formulation approaches in meat based functional
662 foods. Technological options for replacement of meat fats by non-meat fats. *Trends in Food*
663 *Science and Technology*, 18, 567-578.

664 Jiménez-Colmenero, F., Ayo, J., & Carballo, J. (2005). Physicochemical properties of low sodium
665 frankfurter with added walnut: Effect of transglutaminase combined with caseinate, KCl and
666 dietary fibre as salt replacers. *Meat Science*, 69, 781-788.

667 Jiménez-Colmenero, F., Carballo, J., & Cofrades, S. (2001). Healthier meat and meat products:
668 Their role as functional foods. *Meat Science*, 59, 5-13.

669 Jiménez-Colmenero, F. Reig., M., & Toldrá, F. (2006). New approaches for the development of
670 functional meat products. In: Nollet L. M. L. Toldrá, F. (eds). *Advanced Technologies for*
671 *Meat Processing*. pp. 275-308, Boca Raton London, New York: Taylor & Francis Group.

672 Jiménez-Colmenero, F., Serrano, A., Ayo, J., Solas, M. T. Cofrades, S., & Carballo, J. (2003).
673 Physicochemical and sensory characteristics of restructured beef steak with added walnuts.
674 *Meat Science*, 65, 1391-1397.

675 Librelotto, J., Bastida, S., Serrano, A., Cofrades, S., Jiménez-Colmenero, F., & Sánchez-Muniz, F.
676 J. (2008). Changes in fatty acids and polar material of restructured low-fat or walnut-added
677 steaks pan-fried in olive oil. *Meat Science*, 80, 431-441.

678 Librelotto, L., Bastida, S., Zulin-Botega, D., Jiménez-Colmenero, F., & Sánchez-Muniz, F. J.
679 (2009). Effect of long frozen storage in the formation of triglyceride alteration compounds
680 of pan-fried functional restructured beef steaks. *Meat Science*, 81, 726-730.

681 Mackness, M. I., Mackness, B., Durrington, P. N., Fogelman, A. M., Berliner, J., Lysis, A. J.,
682 Navab, M., Shih, D., & Fonarow, G. C. (1998). Paraoxonase and coronary heart disease.
683 *Current Opinion in Lipidology*, 9, 319-24.

684 MAPA (2003). Ministerio de Agricultura, Pesca y Alimentación. www.mapya.es. Accessed
685 03/03/2004.

686 Mensink, R. P., Aro, A., Den Hond, E., German, J. B., Griffin, B. A., ter Meer, H. U., Mutanen, M.,
687 Pannemans, D., & Stahl, W. (2003). PASSCLAIM. Diet-related cardiovascular disease.
688 *European Journal of Nutrition*, 42 (suppl.1), 6-27.

689 Muguerza, E., Gimeno, O., Ansorena, D., & Astiasarán, I. (2004). New formulations for healthier
690 dry fermented sausages: a review. *Trends in Food Science and Technology*, 15, 452-457.

691 Murray, M. & Pizzorno, J. (1999). Procyanidolic oligomeriers. In: Murray M. Pizzorno J, eds. *The*
692 *Textbook of Natural Medicine*. (pp. 899-902). 2nd ed. London: Churchill Livington.

693 Nus, M., Frances, F., Librelotto, J., Canales, A., Corella, D., Sanchez-Montero, J. M., & Sanchez-
694 Muniz, F. J. (2007). Arylesterase activity and antioxidant status depend on PON1-Q192R
695 and PON1-L55M polymorphisms in subjects with increased risk of cardiovascular disease
696 consuming walnut-enriched meat. *Journal of Nutrition*, 137, 1783-1788.

697 Nus, M., Ruperto, M., & Sánchez-Muniz, F. J. (2004). Nuts, cardio and cerebrovascular risks. A
698 Spanish perspective. *Archivos Latinoamericanos de Nutrición*, 54, 137-148.

699 Nus, M., Sánchez-Muniz, F. J., & Sánchez-Montero, J. M. (2006). A new method for the
700 determination of arylesterase activity in human serum using simulated body fluid.
701 *Atherosclerosis*, 188, 155–159.

702 Olmedilla-Alonso, B., Granado-Lorencio, F., Herrero-Barbudo, C., Blanco-Navarro, I., & Sánchez-
703 Muniz, F. J. (2005). Productos cárnicos funcionales preparados con nuez. Evaluación del
704 efecto funcional. (Parte 3). *CTC Alimentación*, 24, 37-41.

705 Olmedilla-Alonso, B., Granado-Lorencio, F., Herrero-Barbudo, C., & Blanco-Navarro, I. (2006).
706 Nutritional approach for designing meat-based functional food products with nuts. *Critical*
707 *Review in Food Science and Nutrition*, 46, 537-542.

708 Olmedilla-Alonso, B., Granado-Lorencio, F., Herrero-Barbudo, C., Blanco-Navarro, I., Blázquez-
709 García, S., & Pérez-Sacristán, B. (2008). Consumption of restructured meat products with
710 added walnuts has a cholesterol-lowering effect in subjects at high cardiovascular risk: a

711 randomised, crossover, placebo-controlled study. *Journal of the American College of*
712 *Nutrition*, 27, 342-348.

713 Ravai, M. (1995). California walnuts. The natural way to healthier heart. *Nutrition Today*, 30, 173.

714 Robert, L., Godeau, G., Gavignet-Jeannin, C., Groult, N., Six, C., & Robert, A. M. (1990) The
715 effect of procyanidolic oligomers on vascular permeability. A study using quantitative
716 morphology. *Pathologie-Biologie (Paris)*, 38, 608-616.

717 Ruiz-Capillas, C., Cofrades, S., Serrano, A., & Jiménez-Colmenero, F. (2004). Biogenic amines in
718 restructured beef steaks as affected by added walnuts and chilling storage. *Journal of Food*
719 *Protection*, 67, 607-609.

720 Sabaté, J. (1993). Does nut consumption protect against ischaemic heart disease?. *European*
721 *Journal of Clinical Nutrition*, 47, S71-S75.

722 Sabaté, J., Fraser, G.E., Burke, K., Knutsen, S., Bennett, H., & Lindsted, K.D. (1993). Effects of
723 walnuts on serum lipids levels and blood pressure in normal men. *The New England Journal*
724 *of Medicine*, 328, 603-607.

725 Salas-Salvadó, J., Fernández-Ballart J., Ros, E., Martínez-González, M. A., Fitó, M., Estruch, R., et
726 al., (2008) Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome
727 status. *Archives of Internal Medicine*, 168, 2449-2458.

728 Salas-Salvadó, J., García-Arellano, A., Estruch, R., Márquez-Sandoval, F., Corella, D., et al.
729 PREDIMED investigators. (2008). Components of the Mediterranean-type food pattern and
730 serum inflammatory markers among patients at high risk for cardiovascular disease.
731 *European Journal of Clinical Nutrition*, 62, 651-659.

732 Sánchez-Muniz, F. (2004). Alimentos funcionales: carne y derivados cárnicos. Presente y
733 perspectivas. In: F. Jiménez-Colmenero, F. J. Sánchez-Muniz, & B. Olmedilla (Eds). *La*
734 *Carne y Productos Cárnicos como Alimentos Funcionales*. (pp. 39-58). Madrid.
735 editec@red.

736 Serrano, A., Cofrades, S., & Jiménez-Colmenero, F. (2004). Transglutaminase as binding agent in
737 fresh restructured beef steak with added walnuts. *Food Chemistry*, 85, 423-429.

738 Serrano, A., Cofrades, S., & Jiménez-Colmenero, F. (2006). Characteristics of restructured beef
739 steak with different proportions of walnut during frozen storage. *Meat Science*, 72, 108-115.

740 Serrano, A., Cofrades, S., Ruiz-Capillas, C., Olmedilla-Alonso, B., Herrero-Barbudo, C., &
741 Jiménez-Colmenero, F. (2005). Nutritional profile of restructured beef steak with added
742 walnuts. *Meat Science*, 70, 647-654.

743 Serrano, A., Librelotto, J., Cofrades, S. Sánchez-Muniz, F. J., & Jiménez Colmenero, F. (2007).
744 Composition and physicochemical characteristics of restructured beef steaks containing
745 walnuts as affected by cooking method. *Meat Science*, 77, 304-313.

746 Sies, H. (1991). Oxidative stress: Oxidants and antioxidants. San Diego: Academic Press.

747 Spanish Patent Application N° solicitud 200300367. Productos cárnicos con compuestos bioactivos
748 cardiosaludables incorporados mediante la adición de frutos secos, preferentemente nuez".
749 Publicado por la Oficina Española de Patentes y Marcas (ES 2 216 699), 16 octubre 2004.

750 Spanish Patent Application N° solicitud 200400548. Mejora de la patente productos cárnicos con
751 compuestos bioactivos cardiosaludables incorporados mediante la adición de frutos secos,
752 preferentemente nuez". Publicado por la Oficina Española de Patentes y Marcas (ES2 245
753 218), 16 diciembre 2005.

754 Szczeklik, A., Gryglewski, R. J., Domagala, B., Dworski, R., & Basista, M. (1985). Dietary
755 supplementation with vitamin E in hyperlipoproteinemias: effects on plasma lipid
756 peroxides, antioxidant activity, prostacyclin generation and platelet aggregability. *Journal of*
757 *Thrombosis and Haemostasis*, 54, 425-430.

758 Tyrovolas, S., & Panagiotakos, D. B. (2009). The role of Mediterranean type of diet on the
759 development of cancer and cardiovascular disease, in the elderly: A systematic review.
760 *Maturitas*, 65:122-130.

761 USDA (2005). U.S. Department of Agriculture, Agricultural Research Service. USDA National
762 nutrient database for standard reference, Release 18. Nutrient Data Laboratory Home Page,
763 2005, <http://www.ars.usda.gov/ba/bhnrc/ndl> Accessed 12/10/2005.

764 WCRF/AICR (1997). Food, nutrition and the prevention of cancer: a global perspective. World
765 Cancer Research Foundation & American Institute for Cancer Research (USA).

766 WHO (2003). Diet, Nutrition and the prevention of chronic diseases. *WHO Technical report series*
767 916. Geneva (Switzerland).
768 <http://www.fao.org/docrep/005/AC911E/AC911E00.HTM#Contents> Accessed 14/10/2004.

769 WHO (2007). Cardiovascular diseases (CVDs). Fact sheet N° 317. February 2007.
770 <http://www.who.int/mediacentre/factsheets/fs317/en/index.html>. Accessed 06/22/2009

771 WHO (2009). Cardiovascular disease: prevention and control.
772 <http://www.who.int/dietphysicalactivity/publications/facts/cvd/en/>. Accessed 06/22/2009.